Immunological,Clinical and Epidemiological Aspects of an HIV-1 Positive Drug Abuser Cohort

Abstract

We analyzed a cohort of intravenous drug abusers with HIV-1 disease attending our institute in the years 1985–1993. We focused particular attention on the epidemiological analysis of patients, and their clinical, immunological and infectious conditions. The significance of biological markers, particulary CD4+ lymphocyte count and the occurence of other viral infections such as Cytomegalovirus, Epstein-Barr virus, Herpes Simplex virus and Hepatitis B and C viruses in the progress of HIV-1 disease were evaluated. At least two-thirds of the patients at different stages of HIV-1 were treated with antiretroviral drugs: zidovudine (AZT) from 1987 up to the present and more recently didanosine (DDI) alone or in combination with AZT. Psychological and behavioral aspects of our HIV-1 infected drug abusers, in particular needle exchange and condom use, were analyzed.

Get full access to this article

View all access options for this article.

References

Aiuti

1983 La sindrome da immunodeficienza acquisita (AIDS). Immunologia Clinica e sperimentale 2: 67–74.

Aiuti

Sirianni

M. C.

Mezzaroma

D'Offizi

G. P.

Pesce

A. M.

Papetti

Ensoli

Luzi

1989 HIV-1 infection: Epidemiological features and immunological alteration during the natural history of disease. Clinical Immunology and Immunopathology 50: S157–S165.

Barré-Sinoussi

Chermann

J. C.

Rey

Nugeyre

M. T.

Chamaret

Gruest

Dauguet

Axler-Blin

Vezinet-Brun

Rouzioux

Rozenbaum

Montagnier

1983 Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–71.

Centers for Disease Control 1986 Classification system for human T-lymphotropic virus typeIII/lymphadenopathy-associated virus infection. Morbidity and Mortality Weekly Report 35: 334–9.

Centers for Disease Control 1989 Update: Acquired immunodeficiency syndrome associated with intravenous drug use – United States 1988. Morbidity and Mortality Weekly Report 38: 165–70.

Centers for Disease Control 1991 Extension of public comment for revision of HIV infection classification system and expansion of AIDS surveillance case definition. Morbidity and Mortality Weekly Report 40: 891.

Collier

A. C.

Bozette

Coombs

R. W.

Causey

D. M.

1990 A pilot study of low-dose zidovudine in human immunodeficiency virus infection. New England Journal of Medicine 323: 1015–21.

Di Ventura

Eboli

Rialti

Siboldi

Carta

D'Offizi

Guerra

Mezzaroma

Aiuti

1993a Changes in sexual behavior among HIV positive people: Before and after. European Journal of Medical Sexology 8: 164–9.

Di Ventura

Eboli

Rialti

Siboldi

Angelini

Carta

D'Offizi

Ferrara

Mezzaroma

Aiuti

1993b Trasformazioni delle abitudini sessuali in soggetti sieropositivi: Una ricerca sul prima e dopo. Rivista di Scienze Sessuologiche 3: 49–54.

10.

Easterbrook

P. J.

Emami

Gazzard

1993 Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 7: 959–67.

11.

Fahey

J. L.

Taylor

J. M .G.

Detels

Hofmann

1990 The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. New England Journal of Medicine 322: 166–72.

12.

Fernàndez-Cruz

Desco

Montes

M. Garcia

Longo

Gonzales

Zabay

J. M.

1990 Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 1: 105–11.

13.

Fischl

M. A.

Richman

D. D.

Grieco

M. H.

1987 The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS -related complex. New England Journal of Medicine 317:185–91.

14.

Fischl

M. A.

Parker

C. B.

Pettinelli

C. A.

1990a A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. New England Journal of Medicine 323: 1009–14.

15.

Fischl

M. A.

Richman

D. D.

Hansen

Collier

A. C.

1990b The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: A double-blind, placebo-controlled trial. Annals of Internal Medicine 112: 727–37.

16.

Gallo

R. C.

Sarin

P. S.

Gelmann

E. P.

Robert-Guroff

Richardson

Kalyanaraman

V. S.

Mann

Sidhu

G. D.

Stahl

R. E.

Zolla-Pazner

Leibowitch

Popovic

1983 Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220: 865–7.

17.

Gates

J. R.

Collado

Budner

N. S.

Schoenbaum

E. E.

1991 Retaining participation in a prospective study of HIV among intravenous drug users (IVDUs) in New York City. In Abstract of the Seventh International Conference on AIDS, Florence, Italy, June 16–21, vol. 2. Rome Istituto Superiore di Sanità.

18.

Gazzard

B. G.

1992 When should asymptomatic patients with HIV infection be treaated with zidovudine. British Medical Journal 304: 456–61.

19.

Luzi

Mezzaroma

D'Offizi

G. P.

Valdarchi

Aiuti

1988 Constant information is needed to prevent the spread of HIV-1 in Italy. Immunologia Clinica e sperimentale 7(2): 105–7.

20.

Luzi

Ensoli

Turbessi

Scarpati

Aiuti

1985 Transmission of HTLV III infection by heterosexual contact. Lancet II: 1018.

21.

MacDonell

K. B.

Chmiel

J. S.

Poggensee

Phair

J. P.

1990 Predicting progression to AIDS: Combined usefulness of CD4 lymphocyte counts and p24 antigenemia. American Journal of Medicine 89: 706–12.

22.

Moore

R. D.

Hidalgo

Sugland

B. W.

Chaisson

R. E.

1991 Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England Journal of Medicine 324: 1412–6.

23.

Osservatorio Epidemiologico Regionale - Lazio 1990 Epidemia di infezione da HIV e AIDS nel Lazio. Progetto Salute 15: 1–72.

24.

Pantaleo

Graziosi

Demarest

J. F.

Butini

Montroni

Fox

C. H.

Orenstein

J. M.

Kotler

D. P.

Fauci

A. S.

1993 HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355–8.

25.

Phillips

A. N.

Lee

C. A.

Elfort

Janossy

1991 Serial CD4 lymphocyte counts and development of AIDS. Lancet 336:389–92.

26.

Rezza

Lazzarin

A. S.

Angarano

Sinicco

Prister

Ortona

Barbanera

Gafà

Tirelli

Slasse

Ricchi

Aiuti

Manniti-Ippolito

1989 The natural history of HIV infection in intravenous drug users. Risk of disease progression in a cohort of seroconverters. AIDS 3: 87–90.

27.

Schoenbaum

E. E.

Hartel

Selwyn

P. A.

Klein

R. S.

, 1989 Risk factors for human immunodeficiency virus infection in intravenous drug users. New England Journal of Medicine 321:874–9.

28.

Selwyn

P. A.

Feingold

A. R.

Hartel

1988 Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 2: 267–72.

29.

Selwyn

P. A.

Hartel

Lewis

V. A.

1989a A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New England Journal of Medicine 320: 545–50.

30.

Selwyn

P. A.

Hartel

Wasserman

Drucker

1989b Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. American Journal of Public Health 79: 1358–62.

31.

Selwyn

P. A.

Alcabes

Hartel

Buono

Schoenbaum

E. E.

Klein

R. S.

Davenny

Friedland

G. H.

1992 Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. New England Journal of Medicine 327: 1697–703.

32.

Sirianni

M. C.

Rossi

Moroni

Romagnani

Lazzarin

A. S.

Carbonari

Scarpati

Mariani

Manconi

P. E.

Del Giacco

Aiuti

1986 Demonstration of antibodies to human T-lymphotropic retrovirus type III in lymphadenopathy syndrome patients and in individuals at risk for acquired immune deficiency syndrome (AIDS) in Italy. American Journal of Epidemiology 123: 308–15.

33.

Solano

Costa

Salvati

Bertini

Aiuti

Mezzaroma

1991 Fattori psicosociali e situazione clinico-immunologica nell'infezione da HIV: Studio su 100 soggetti asintomatici e LAS. Mediana Psicosomatica 36: 3–15.

34.

Solano

Costa

Salvati

Coda

Aiuti

Mezzaroma

Bertini

1993 Psychosocial factors and clinical evolution in HIV-1 infection: A longitudinal study. Journal of Psychosomatic Research 37: 39–51.

35.

Weber

Ledergerber

Opravil

Siegenthaler

Luthy

1990 Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. British Medical Journal 301: 1362–5.

36.

World Health Organization 1991 Acquired immunodeficiency syndrome (AIDS): WHO European region - update to 30 September 1990. Weekly Epidemiological Report 66: 33–8.

37.

Zangerle

Fuchs

Reibnegger

Fritsch

Wachter

1991 Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 5: 985–91.